{"id":436,"date":"2023-09-14T15:26:37","date_gmt":"2023-09-14T13:26:37","guid":{"rendered":"https:\/\/cfnorge.bwod.dev\/?page_id=436"},"modified":"2025-11-10T14:59:08","modified_gmt":"2025-11-10T13:59:08","slug":"slik-er-behadlingen-for-cf-med-kaftrio","status":"publish","type":"page","link":"https:\/\/cfnorge.no\/en\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/","title":{"rendered":"Slik er behadlingen for CF med Kaftrio"},"content":{"rendered":"<p>[et_pb_section fb_built=&raquo;1&#8243; next_background_color=&raquo;#ffffff&raquo; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; top_divider_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; top_divider_height=&raquo;55px&raquo; top_divider_flip=&raquo;vertical&raquo; bottom_divider_style=&raquo;wave&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22top_divider_color%22%93,%22gcid-9e2f3af2-1007-4221-b250-8e35d98c5991%22:%91%22background_color%22%93}&raquo;][et_pb_row _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; custom_padding=&raquo;11px||4px|||&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_column type=&raquo;4_4&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_text _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; header_font=&raquo;Poppins|600|||||||&raquo; header_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; custom_margin=&raquo;0px||0px||false|false&raquo; custom_padding=&raquo;0px||0px||false|false&raquo; global_colors_info=&raquo;{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22header_text_color%22%93}&raquo;]<\/p>\n<h1>Treatment for CF with Kaftrio<\/h1>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; custom_margin=&raquo;0px|auto|68px|auto|false|false&raquo; custom_padding=&raquo;0px||||false|false&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_column type=&raquo;4_4&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_text _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; text_font=&raquo;Poppins|300|||||||&raquo; text_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; text_font_size=&raquo;16px&raquo; text_line_height=&raquo;1.8em&raquo; global_colors_info=&raquo;{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22text_text_color%22%93}&raquo;]Kaftrio\/Kalydeco er en innovativ \u00e5rsaks-korrigerende behandling for cystisk fibrose. Behandlingen viser opptil 14 prosentpoeng bedring i lungekapasitet i en studie blant personer med CF med minst en 508del-mutasjon i CFTR-genet.<\/p>\n<p>In Norway, Kaftrio\/Kalydeco was officially approved for public funding on April 25, 2022, by the Norwegian Decisions Forum. On May 27, 2024, it was also approved for use in children aged 2-6 years. Starting July 1, 2024, Kaftrio will be available for children with cystic fibrosis who have at least one F508del mutation.<\/span>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&raquo;1&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo; min_height__hover_enabled=&raquo;off|desktop&raquo;][et_pb_row column_structure=&raquo;1_3,1_3,1_3&#8243; use_custom_gutter=&raquo;on&raquo; gutter_width=&raquo;2&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; custom_padding=&raquo;0px|||||&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_column type=&raquo;1_3&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_toggle title=&raquo;Hva er Kaftrio\/Kalydeco?&raquo; open_toggle_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; closed_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; toggle_icon=&raquo;&#x22;||divi||400&#8243; use_icon_font_size=&raquo;on&raquo; icon_font_size=&raquo;18px&raquo; open_icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_icon=&raquo;&#x21;||divi||400&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; title_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; title_font=&raquo;|600|||||||&raquo; body_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; body_link_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; custom_padding=&raquo;35px||35px||false|false&raquo; border_width_all=&raquo;0px&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{%22gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05%22:%91%22icon_color%22,%22open_toggle_text_color%22,%22title_text_color%22,%22body_link_text_color%22,%22open_icon_color%22%93,%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22body_text_color%22%93,%22gcid-9e2f3af2-1007-4221-b250-8e35d98c5991%22:%91%22closed_toggle_background_color%22,%22open_toggle_background_color%22%93}&raquo;]<\/p>\n<p>Kaftrio (also known as Kalydeco) is a cutting-edge, disease-correcting treatment for cystic fibrosis.<\/p>\n<p>It combines three active ingredients - elexacaftor, tezacaftor, and ivacaftor.<\/p>\n<p>Together they work to target the CFTR protein responsible for cystic fibrosis. This treatment is known as a CFTR modulator.<\/p>\n<p><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:150}\"><\/span><\/p>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kaftrio-epar-product-information_no.pdf\"><span data-contrast=\"none\">Preparatomtale Kaftrio p\u00e5 NORSK<\/span><\/a><span data-contrast=\"none\">For more details on specific minimal function mutations studied, check the Kaftrio product information (Section 5.1, pages 11-12) on the Norwegian Medicines Agency website.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\"><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kaftrio\"><span data-contrast=\"none\">Comprehensive approval details can be found on the EMA website.<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true}\">\u00a0<\/span><\/li>\n<\/ul>\n<p>[\/et_pb_toggle][et_pb_toggle title=&raquo;N\u00e5r man ikke kan bruke Kaftrio&raquo; open_toggle_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; closed_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; toggle_icon=&raquo;&#x22;||divi||400&#8243; use_icon_font_size=&raquo;on&raquo; icon_font_size=&raquo;18px&raquo; open_icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_icon=&raquo;&#x21;||divi||400&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; title_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; title_font=&raquo;|600|||||||&raquo; body_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; body_link_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; custom_padding=&raquo;35px||35px||false|false&raquo; border_width_all=&raquo;0px&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{%22gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05%22:%91%22icon_color%22,%22open_toggle_text_color%22,%22title_text_color%22,%22body_link_text_color%22,%22open_icon_color%22%93,%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22body_text_color%22%93,%22gcid-9e2f3af2-1007-4221-b250-8e35d98c5991%22:%91%22closed_toggle_background_color%22,%22open_toggle_background_color%22%93}&raquo;]<\/p>\n<p>For those who cannot use Kaftrio, it can be extra difficult in a community characterized by collective jubilation. As an NFCF member, Bernhard (30) describes it so well: \"It can feel like being left at the bus stop when the bus has left.\" Click on the link below to read more about this important topic, and how NFCF, together with international partners, works to ensure future treatment options for more people with CF.<\/p>\n<p><a href=\"https:\/\/cfnorge.no\/en\/a-sta-igjen-pa-busstoppet-nar-man-ikke-kan-bruke-kaftrio\/?fbclid=IwY2xjawFH8n1leHRuA2FlbQIxMQABHYX6owCHBonU5ovx1z0cJXZ2BM6yv2FEgnsC2st44Gmmc9BYyDZi2JA-kw_aem_9Y9sWwtt65dyBcy1cdFhrQ\">Being left at the bus stop - When you can't use Kaftrio\u00a0<\/a><\/p>\n<p>[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&raquo;1_3&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_toggle title=&raquo;Hvem kan f\u00e5 Kaftrio\/Kalydeco?&raquo; open_toggle_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; closed_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; toggle_icon=&raquo;&#x22;||divi||400&#8243; use_icon_font_size=&raquo;on&raquo; icon_font_size=&raquo;18px&raquo; open_icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_icon=&raquo;&#x21;||divi||400&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; title_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; title_font=&raquo;|600|||||||&raquo; body_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; body_link_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; custom_padding=&raquo;35px||35px||false|false&raquo; title_line_height_tablet=&raquo;&raquo; title_line_height_phone=&raquo;1.4em&raquo; title_line_height_last_edited=&raquo;on|phone&raquo; border_width_all=&raquo;0px&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{%22gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05%22:%91%22icon_color%22,%22open_toggle_text_color%22,%22title_text_color%22,%22body_link_text_color%22,%22open_icon_color%22%93,%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22body_text_color%22%93,%22gcid-9e2f3af2-1007-4221-b250-8e35d98c5991%22:%91%22open_toggle_background_color%22,%22closed_toggle_background_color%22%93}&raquo;]<\/p>\n<div class=\"flex flex-grow flex-col max-w-full\">\n<div data-message-author-role=\"assistant\" data-message-id=\"5d0ab7be-8daf-42db-a6cf-96ae7efeced8\" dir=\"auto\" class=\"min-h-[20px] text-message flex flex-col items-start whitespace-pre-wrap break-words [.text-message+&amp;]:mt-5 juice:w-full juice:items-end overflow-x-auto gap-2\">\n<div class=\"flex w-full flex-col gap-1 juice:empty:hidden juice:first:pt-[3px]\">\n<div class=\"markdown prose w-full break-words dark:prose-invert light\">\n<p>Kaftrio\/Kalydeco is approved for use in people with cystic fibrosis who are 6 years or older and have either one F508del mutation and one minimal function mutation (heterozygotes) or two F508del mutations (homozygotes). Starting July 1, 2024, Kaftrio will also be available in Norway for children aged 2-6 years who have at least one F508del mutation.<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p><span style=\"font-size: medium;\"><strong>Best treatment for those with one F508del and minimal function mutation<\/strong><\/span><\/p>\n<p>Kaftrio\/Kalydeco is the most effective disease-correcting medication for individuals with one F508del mutation and one minimal function mutation. It represents a significant advancement in cystic fibrosis treatment. Minimal function mutations lead to CFTR proteins with very limited activity, but Kaftrio\/Kalydeco helps increase the amount of active CFTR protein<\/p>\n<p>[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&raquo;1_3&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_toggle title=&raquo;Effekten til Kaftrio\/Kalydeco&raquo; open_toggle_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; closed_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; toggle_icon=&raquo;&#x22;||divi||400&#8243; use_icon_font_size=&raquo;on&raquo; icon_font_size=&raquo;18px&raquo; open_icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_icon=&raquo;&#x21;||divi||400&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; title_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; title_font=&raquo;|600|||||||&raquo; body_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; body_link_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; custom_padding=&raquo;35px||35px||false|false&raquo; border_width_all=&raquo;0px&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{%22gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05%22:%91%22icon_color%22,%22open_toggle_text_color%22,%22title_text_color%22,%22body_link_text_color%22,%22open_icon_color%22%93,%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22body_text_color%22%93,%22gcid-9e2f3af2-1007-4221-b250-8e35d98c5991%22:%91%22open_toggle_background_color%22,%22closed_toggle_background_color%22%93}&raquo;]<\/p>\n<p>Studies have shown that Kaftrio\/Kalydeco can improve lung function by up to 14 percentage points in FEV1 compared to a placebo in people with one F508del and one minimal function mutation. For those with two F508del mutations, it has been shown to increase lung function by 10 percentage points compared to Symkevi, a previous CFTR modulator.<\/p>\n<p>Kaftrio\/Kalydeco contributes to a healthier CF population with fewer chronic infections, fewer exacerbations, and better nutritional status. Common side effects include acne, headache, diarrhea, and nasal congestion. The medication is taken as tablets twice daily.<\/p>\n<p>Ongoing monitoring by healthcare professionals is essential to manage both the effectiveness and any potential side effects of the treatment.<\/p>\n<p>[\/et_pb_toggle][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&raquo;1_2,1_2&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; custom_margin=&raquo;50px|auto||auto|false|false&raquo; custom_margin_tablet=&raquo;50px|auto||auto|false|false&raquo; custom_margin_phone=&raquo;50px|auto||auto|false|false&raquo; custom_margin_last_edited=&raquo;on|desktop&raquo; custom_padding=&raquo;0px|||||&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_column type=&raquo;1_2&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_text _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; header_font=&raquo;Poppins|600|||||||&raquo; header_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; custom_margin=&raquo;0px||0px||false|false&raquo; custom_padding=&raquo;0px||0px||false|false&raquo; global_colors_info=&raquo;{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22header_text_color%22%93}&raquo;]<\/p>\n<h1><span style=\"font-size: x-large;\"><strong>600 Days of Battle<\/strong><\/span><\/h1>\n<p>[\/et_pb_text][et_pb_text _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; text_font=&raquo;Poppins|300|||||||&raquo; text_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; text_font_size=&raquo;16px&raquo; text_line_height=&raquo;1.8em&raquo; global_colors_info=&raquo;{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22text_text_color%22%93}&raquo;]<\/p>\n<p>The fight to get Kaftrio\/Kalydeco approved in Norway was long and arduous, spanning over 600 days. The Norwegian Cystic Fibrosis Association was steadfast throughout the entire process, and we can now look back with pride at the results of our efforts. The approval in 2022 for patients aged 6 and older, along with the crucial extension in 2024 to include children aged 2-6 years, represents significant victories for the CF community.<\/p>\n<p>These achievements reflect our dedication and perseverance in overcoming substantial challenges. Whether the treatment will be approved for other mutation combinations in the future remains uncertain. However, ongoing drug development and research provide hope for those who currently do not meet the criteria for Kaftrio\/Kalydeco.<\/p>\n<p>As a <a href=\"https:\/\/nfcf.portal.styreweb.com\/arrangement\/ArrangementSession?ID=Innmelding\">member<\/a> of the Norwegian Cystic Fibrosis Association, you play a vital role in supporting our efforts. Your support amplifies our voice with policymakers and decision-makers, helping us achieve these important milestones for you and your family.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&raquo;1_2&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_image src=&raquo;https:\/\/cfnorge.bwod.dev\/wp-content\/uploads\/2024\/06\/kaftrio.png&raquo; title_text=&raquo;kaftrio&raquo; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; custom_margin=&raquo;||-7px|||&raquo; global_colors_info=&raquo;{}&raquo;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&raquo;1&#8243; disabled_on=&raquo;on|on|off&raquo; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; background_color=&raquo;gcid-f60bfea8-f451-489d-8bfd-27e12ee36365&#8243; custom_padding=&raquo;||0px||false|false&raquo; global_colors_info=&raquo;{%22gcid-f60bfea8-f451-489d-8bfd-27e12ee36365%22:%91%22background_color%22%93}&raquo;][et_pb_row column_structure=&raquo;1_2,1_2&#8243; use_custom_gutter=&raquo;on&raquo; gutter_width=&raquo;1&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; custom_margin=&raquo;||0px||false|false&raquo; custom_padding=&raquo;||0px||false|false&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_column type=&raquo;1_2&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_image src=&raquo;https:\/\/cfnorge.bwod.dev\/wp-content\/uploads\/2023\/08\/Stott-oss-illustrasjon-CF-1.png&raquo; title_text=&raquo;St\u00f8tt-oss-illustrasjon-CF&raquo; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; width=&raquo;65%&raquo; module_alignment=&raquo;center&raquo; global_colors_info=&raquo;{}&raquo;][\/et_pb_image][\/et_pb_column][et_pb_column type=&raquo;1_2&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_text _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; header_2_font=&raquo;Poppins|600|||||||&raquo; header_2_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; header_2_font_size=&raquo;30px&raquo; header_3_font=&raquo;Poppins||||||||&raquo; header_3_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; header_3_font_size=&raquo;20px&raquo; header_3_line_height=&raquo;1.5em&raquo; custom_margin=&raquo;74px||18px|||&raquo; global_colors_info=&raquo;{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22header_2_text_color%22,%22header_3_text_color%22%93}&raquo;]<\/p>\n<h2>Support us<\/h2>\n<h3>We are grateful for all<br \/>\ncontributions to our work.<\/h3>\n<p>[\/et_pb_text][et_pb_button button_url=&raquo;@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjQ1NyJ9fQ==@&raquo; button_text=&raquo;Les hvordan her&raquo; _builder_version=&raquo;4.21.0&#8243; _dynamic_attributes=&raquo;button_url&raquo; _module_preset=&raquo;default&raquo; custom_button=&raquo;on&raquo; button_text_size=&raquo;16px&raquo; button_text_color=&raquo;#FFFFFF&raquo; button_bg_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; button_border_width=&raquo;0px&raquo; button_border_radius=&raquo;100px&raquo; global_colors_info=&raquo;{%22gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05%22:%91%22button_bg_color%22%93}&raquo;][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&raquo;1&#8243; disabled_on=&raquo;off|off|on&raquo; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; background_color=&raquo;gcid-f60bfea8-f451-489d-8bfd-27e12ee36365&#8243; custom_padding=&raquo;||0px||false|false&raquo; global_colors_info=&raquo;{%22gcid-f60bfea8-f451-489d-8bfd-27e12ee36365%22:%91%22background_color%22%93}&raquo;][et_pb_row use_custom_gutter=&raquo;on&raquo; gutter_width=&raquo;1&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; custom_margin=&raquo;||0px||false|false&raquo; custom_padding=&raquo;8px||0px||false|false&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_column type=&raquo;4_4&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_text _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; header_2_font=&raquo;Poppins|600|||||||&raquo; header_2_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; header_2_font_size=&raquo;30px&raquo; header_3_font=&raquo;Poppins||||||||&raquo; header_3_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; header_3_font_size=&raquo;20px&raquo; header_3_line_height=&raquo;1.5em&raquo; custom_margin=&raquo;7px||18px|||&raquo; global_colors_info=&raquo;{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22header_2_text_color%22,%22header_3_text_color%22%93}&raquo;]<\/p>\n<h2>Support us<\/h2>\n<h3>We are grateful for all<br \/>\ncontributions to our work.<\/h3>\n<p>[\/et_pb_text][et_pb_button button_url=&raquo;@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjQ1NyJ9fQ==@&raquo; button_text=&raquo;Les hvordan her&raquo; _builder_version=&raquo;4.21.0&#8243; _dynamic_attributes=&raquo;button_url&raquo; _module_preset=&raquo;default&raquo; custom_button=&raquo;on&raquo; button_text_size=&raquo;16px&raquo; button_text_color=&raquo;#FFFFFF&raquo; button_bg_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; button_border_width=&raquo;0px&raquo; button_border_radius=&raquo;100px&raquo; global_colors_info=&raquo;{%22gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05%22:%91%22button_bg_color%22%93}&raquo;][\/et_pb_button][et_pb_image src=&raquo;https:\/\/cfnorge.no\/wp-content\/uploads\/2023\/08\/Stott-oss-illustrasjon-CF-1.png&raquo; title_text=&raquo;St\u00f8tt-oss-illustrasjon-CF&raquo; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; width=&raquo;65%&raquo; width_tablet=&raquo;50%&raquo; width_phone=&raquo;58%&raquo; width_last_edited=&raquo;on|phone&raquo; module_alignment=&raquo;right&raquo; custom_margin=&raquo;||||false|false&raquo; custom_margin_tablet=&raquo;-20px||||false|false&raquo; custom_margin_phone=&raquo;0px||||false|false&raquo; custom_margin_last_edited=&raquo;on|tablet&raquo; custom_padding_tablet=&raquo;||||false|false&raquo; custom_padding_phone=&raquo;||||false|false&raquo; custom_padding_last_edited=&raquo;on|tablet&raquo; global_colors_info=&raquo;{}&raquo;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"<p>Kaftrio ble endelig godkjent i Norge 25. april 2022 ved et vedtak i Beslutningsforum. Kaftrio er en innovativ \u00e5rsakskorrigerende behandling for cystisk fibrose. Behandlingen med Kaftrio gir opptil 14 prosentpoeng bedring i lungekapasitet.  <\/p>","protected":false},"author":1,"featured_media":0,"parent":265,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-436","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Slik er behadlingen for CF med Kaftrio | CF Norge<\/title>\n<meta name=\"description\" content=\"Kaftrio for Cyctisk Fiberose \u2013 CF Norge. Kaftrio er en behandling for cystisk fibrose. I 2022 ble CFTR-modulatoren endelig godkjent i Norge.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cfnorge.no\/en\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Slik er behadlingen for CF med Kaftrio | CF Norge\" \/>\n<meta property=\"og:description\" content=\"Kaftrio for Cyctisk Fiberose \u2013 CF Norge. Kaftrio er en behandling for cystisk fibrose. I 2022 ble CFTR-modulatoren endelig godkjent i Norge.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cfnorge.no\/en\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/\" \/>\n<meta property=\"og:site_name\" content=\"CF Norge\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-10T13:59:08+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cfnorge.no\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/\",\"url\":\"https:\/\/cfnorge.no\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/\",\"name\":\"Slik er behadlingen for CF med Kaftrio | CF Norge\",\"isPartOf\":{\"@id\":\"https:\/\/cfnorge.no\/#website\"},\"datePublished\":\"2023-09-14T13:26:37+00:00\",\"dateModified\":\"2025-11-10T13:59:08+00:00\",\"description\":\"Kaftrio for Cyctisk Fiberose \u2013 CF Norge. Kaftrio er en behandling for cystisk fibrose. I 2022 ble CFTR-modulatoren endelig godkjent i Norge.\",\"breadcrumb\":{\"@id\":\"https:\/\/cfnorge.no\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cfnorge.no\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cfnorge.no\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hjem\",\"item\":\"https:\/\/cfnorge.no\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cystisk fibrose\",\"item\":\"https:\/\/cfnorge.no\/cystisk-fibrose\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Slik er behadlingen for CF med Kaftrio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cfnorge.no\/#website\",\"url\":\"https:\/\/cfnorge.no\/\",\"name\":\"CF Norge\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/cfnorge.no\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cfnorge.no\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cfnorge.no\/#organization\",\"name\":\"CF Norge\",\"url\":\"https:\/\/cfnorge.no\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/cfnorge.no\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cfnorge.no\/wp-content\/uploads\/2024\/06\/CF-Horisontal-logo-2.png\",\"contentUrl\":\"https:\/\/cfnorge.no\/wp-content\/uploads\/2024\/06\/CF-Horisontal-logo-2.png\",\"width\":12334,\"height\":3827,\"caption\":\"CF Norge\"},\"image\":{\"@id\":\"https:\/\/cfnorge.no\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Slik er behadlingen for CF med Kaftrio | CF Norge","description":"Kaftrio for Cyctisk Fiberose \u2013 CF Norge. Kaftrio er en behandling for cystisk fibrose. I 2022 ble CFTR-modulatoren endelig godkjent i Norge.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cfnorge.no\/en\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/","og_locale":"en_GB","og_type":"article","og_title":"Slik er behadlingen for CF med Kaftrio | CF Norge","og_description":"Kaftrio for Cyctisk Fiberose \u2013 CF Norge. Kaftrio er en behandling for cystisk fibrose. I 2022 ble CFTR-modulatoren endelig godkjent i Norge.","og_url":"https:\/\/cfnorge.no\/en\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/","og_site_name":"CF Norge","article_modified_time":"2025-11-10T13:59:08+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cfnorge.no\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/","url":"https:\/\/cfnorge.no\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/","name":"Slik er behadlingen for CF med Kaftrio | CF Norge","isPartOf":{"@id":"https:\/\/cfnorge.no\/#website"},"datePublished":"2023-09-14T13:26:37+00:00","dateModified":"2025-11-10T13:59:08+00:00","description":"Kaftrio for Cyctisk Fiberose \u2013 CF Norge. Kaftrio er en behandling for cystisk fibrose. I 2022 ble CFTR-modulatoren endelig godkjent i Norge.","breadcrumb":{"@id":"https:\/\/cfnorge.no\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cfnorge.no\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cfnorge.no\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hjem","item":"https:\/\/cfnorge.no\/"},{"@type":"ListItem","position":2,"name":"Cystisk fibrose","item":"https:\/\/cfnorge.no\/cystisk-fibrose\/"},{"@type":"ListItem","position":3,"name":"Slik er behadlingen for CF med Kaftrio"}]},{"@type":"WebSite","@id":"https:\/\/cfnorge.no\/#website","url":"https:\/\/cfnorge.no\/","name":"CF Norge","description":"","publisher":{"@id":"https:\/\/cfnorge.no\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cfnorge.no\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/cfnorge.no\/#organization","name":"CF Norge","url":"https:\/\/cfnorge.no\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/cfnorge.no\/#\/schema\/logo\/image\/","url":"https:\/\/cfnorge.no\/wp-content\/uploads\/2024\/06\/CF-Horisontal-logo-2.png","contentUrl":"https:\/\/cfnorge.no\/wp-content\/uploads\/2024\/06\/CF-Horisontal-logo-2.png","width":12334,"height":3827,"caption":"CF Norge"},"image":{"@id":"https:\/\/cfnorge.no\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/cfnorge.no\/en\/wp-json\/wp\/v2\/pages\/436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cfnorge.no\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cfnorge.no\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cfnorge.no\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cfnorge.no\/en\/wp-json\/wp\/v2\/comments?post=436"}],"version-history":[{"count":32,"href":"https:\/\/cfnorge.no\/en\/wp-json\/wp\/v2\/pages\/436\/revisions"}],"predecessor-version":[{"id":2228,"href":"https:\/\/cfnorge.no\/en\/wp-json\/wp\/v2\/pages\/436\/revisions\/2228"}],"up":[{"embeddable":true,"href":"https:\/\/cfnorge.no\/en\/wp-json\/wp\/v2\/pages\/265"}],"wp:attachment":[{"href":"https:\/\/cfnorge.no\/en\/wp-json\/wp\/v2\/media?parent=436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}